Seres therapeutics presents research from its early-stage microbiome therapeutic oncology programs at the 2021 american society of clinical oncology (asco) annual meeting

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, today announced data from their collaboration with the university of cologne (kÖln, germany) demonstrating that decreased microbiome diversity in allogeneic hematopoietic stem cell transplantation (hsct) recipients is associated with poor clinical outcomes including mortality and increased incidence of intestinal graft-versus-host disease (gvhd). the data are being presented in
MCRB Ratings Summary
MCRB Quant Ranking